FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221008110> ?p ?o ?g. }

• W4221008110 endingPage "235" @default.
• W4221008110 startingPage "228" @default.
• W4221008110 abstract "Triple-negative breast cancer (TNBC) is an aggressive subtype, where no effective therapies have been established for it. Searching for therapeutic targets for TNBC patients is the aim of the current research. Poly adenosine diphosphate ribose polymerase (PARP1) inhibitors are promising antitumor therapy that have a high potency in BRCA1-deficient breast cancers. Forty TNBC patients who received neoadjuvant chemotherapy (NAC) were enrolled in this study, and evaluated for PARP1, BRCA1, and Androgen receptor (AR) immunohistochemical expression before and after receiving NAC. Data of patients' clinical and pathological responses to the chemotherapy were collected and finally analyzed. The immunohistochemical results revealed 10 cases (25%) positive for AR, while 18 cases (45%) and 22 cases (55%) expressed PARP1 at low and high levels, respectively. Twelve cases (30%) and 28 cases (70%) expressed BRCA1 at low and high levels, respectively. There was a significant difference between PARP1 expression in normal and malignant tissues (P < 0.001). Higher PARP1 expression was correlated with a better overall clinical response (OAR) and pathological complete response (pCR) (P = 0.018, 0.01 respectively). Co-expression of both PARP1 & BRCA1 was correlated with OAR and pCR. Chemotherapy decreases PARP1 protein levels in matched patient samples (P = 0.015). Positive AR expression was correlated with BRCA1 overexpression. PARP1 is highly expressed in TNBC with a better OAR and pCR especially in cases with high BRCA1, so it might be considered as a therapeutic target for this risky group. El cáncer de mama triple negativo (TNBC) es un subtipo agresivo, donde no se han establecido terapias efectivas para este cáncer. La búsqueda de dianas terapéuticas para pacientes con TNBC es el objetivo de la investigación actual. Los inhibidores de la poli adenosina difosfato ribosa polimerasa (PARP1) son prometedores terapia antitumoral que tienen una alta potencia en los cánceres de mama deficientes de BRCA1. Cuarenta pacientes de TNBC que recibieron quimioterapia neoadyuvante (NAC) se inscribieron en este estudio y se evaluaron para la expresión inmunohistoquímica de PARP1, BRCA1 y receptores de andrógenos (AR) antes y después de recibir NAC. Se recogieron y finalmente se analizaron los datos de las respuestas clínicas y patológicas de los pacientes a la quimioterapia. Los resultados inmunohistoquímicos revelaron 10 casos (25%) positivos para AR, mientras que 18 casos (45%) y 22 casos (55%) expresaron PARP1 en niveles bajos y altos, respectivamente. Doce casos (30%) y 28 casos (70%) expresaron BRCA1 en niveles bajos y altos, respectivamente. Hubo una diferencia significativa entre la expresión de PARP1 en tejidos normales y malignos (P 0.001). Una mayor expresión de PARP1 se correlacionó con una mejor respuesta clínica global (OAR) y una respuesta patológica completa (pCR) (P = 0,018, 0,01 respectivamente). La co-expresión de ambos PARP1 y BRCA1 se correlacionó con OAR y pCR. La quimioterapia disminuye los niveles de proteína PARP1 en muestras de pacientes emparejadas (P = 0,015). La expresión positivos de AR se correlacionó con la expresión de BRCA1. El PARP1 está muy expresado en TNBC con una mejor OAR y pCR especialmente en casos con BRCA1 alto, por lo que podría ser considerado como una diana terapéutica para este grupo de riesgo." @default.
• W4221008110 created "2022-04-03" @default.
• W4221008110 creator A5023377919 @default.
• W4221008110 creator A5040475223 @default.
• W4221008110 creator A5040846085 @default.
• W4221008110 creator A5047249373 @default.
• W4221008110 creator A5049322033 @default.
• W4221008110 creator A5050596095 @default.
• W4221008110 creator A5071772254 @default.
• W4221008110 creator A5087138778 @default.
• W4221008110 date "2022-10-01" @default.
• W4221008110 modified "2023-10-16" @default.
• W4221008110 title "PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy" @default.
• W4221008110 cites W1536290683 @default.
• W4221008110 cites W1894822026 @default.
• W4221008110 cites W1904491573 @default.
• W4221008110 cites W1965006127 @default.
• W4221008110 cites W1967761175 @default.
• W4221008110 cites W1973268287 @default.
• W4221008110 cites W1974496157 @default.
• W4221008110 cites W1985804387 @default.
• W4221008110 cites W2013132407 @default.
• W4221008110 cites W2045041545 @default.
• W4221008110 cites W2071535912 @default.
• W4221008110 cites W2080497992 @default.
• W4221008110 cites W2085181480 @default.
• W4221008110 cites W2103533058 @default.
• W4221008110 cites W2132360977 @default.
• W4221008110 cites W2136879321 @default.
• W4221008110 cites W2138929540 @default.
• W4221008110 cites W2145469049 @default.
• W4221008110 cites W2157375575 @default.
• W4221008110 cites W2170602872 @default.
• W4221008110 cites W2221164499 @default.
• W4221008110 cites W2280211319 @default.
• W4221008110 cites W2566635818 @default.
• W4221008110 cites W2585107430 @default.
• W4221008110 cites W2615036580 @default.
• W4221008110 cites W3030957531 @default.
• W4221008110 cites W4255406860 @default.
• W4221008110 doi "https://doi.org/10.1016/j.senol.2021.08.002" @default.
• W4221008110 hasPublicationYear "2022" @default.
• W4221008110 type Work @default.
• W4221008110 citedByCount "0" @default.
• W4221008110 countsByYear W42210081102023 @default.
• W4221008110 crossrefType "journal-article" @default.
• W4221008110 hasAuthorship W4221008110A5023377919 @default.
• W4221008110 hasAuthorship W4221008110A5040475223 @default.
• W4221008110 hasAuthorship W4221008110A5040846085 @default.
• W4221008110 hasAuthorship W4221008110A5047249373 @default.
• W4221008110 hasAuthorship W4221008110A5049322033 @default.
• W4221008110 hasAuthorship W4221008110A5050596095 @default.
• W4221008110 hasAuthorship W4221008110A5071772254 @default.
• W4221008110 hasAuthorship W4221008110A5087138778 @default.
• W4221008110 hasConcept C121608353 @default.
• W4221008110 hasConcept C126322002 @default.
• W4221008110 hasConcept C143998085 @default.
• W4221008110 hasConcept C181199279 @default.
• W4221008110 hasConcept C182979987 @default.
• W4221008110 hasConcept C204232928 @default.
• W4221008110 hasConcept C207886595 @default.
• W4221008110 hasConcept C2776694085 @default.
• W4221008110 hasConcept C2778480876 @default.
• W4221008110 hasConcept C2780110267 @default.
• W4221008110 hasConcept C2780192828 @default.
• W4221008110 hasConcept C502942594 @default.
• W4221008110 hasConcept C530470458 @default.
• W4221008110 hasConcept C55493867 @default.
• W4221008110 hasConcept C61367390 @default.
• W4221008110 hasConcept C71924100 @default.
• W4221008110 hasConcept C82381507 @default.
• W4221008110 hasConcept C86803240 @default.
• W4221008110 hasConceptScore W4221008110C121608353 @default.
• W4221008110 hasConceptScore W4221008110C126322002 @default.
• W4221008110 hasConceptScore W4221008110C143998085 @default.
• W4221008110 hasConceptScore W4221008110C181199279 @default.
• W4221008110 hasConceptScore W4221008110C182979987 @default.
• W4221008110 hasConceptScore W4221008110C204232928 @default.
• W4221008110 hasConceptScore W4221008110C207886595 @default.
• W4221008110 hasConceptScore W4221008110C2776694085 @default.
• W4221008110 hasConceptScore W4221008110C2778480876 @default.
• W4221008110 hasConceptScore W4221008110C2780110267 @default.
• W4221008110 hasConceptScore W4221008110C2780192828 @default.
• W4221008110 hasConceptScore W4221008110C502942594 @default.
• W4221008110 hasConceptScore W4221008110C530470458 @default.
• W4221008110 hasConceptScore W4221008110C55493867 @default.
• W4221008110 hasConceptScore W4221008110C61367390 @default.
• W4221008110 hasConceptScore W4221008110C71924100 @default.
• W4221008110 hasConceptScore W4221008110C82381507 @default.
• W4221008110 hasConceptScore W4221008110C86803240 @default.
• W4221008110 hasIssue "4" @default.
• W4221008110 hasLocation W42210081101 @default.
• W4221008110 hasOpenAccess W4221008110 @default.
• W4221008110 hasPrimaryLocation W42210081101 @default.
• W4221008110 hasRelatedWork W1999292713 @default.
• W4221008110 hasRelatedWork W2363661003 @default.
• W4221008110 hasRelatedWork W2367105124 @default.
• W4221008110 hasRelatedWork W2388730008 @default.

• next